+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 100Years
All Genders
ID06947993

Randomized Phase II Study Evaluating Different Doses of GHZ339 Compared to Placebo in Adults with Moderate to Severe Atopic Dermatitis

Led by Novartis Pharmaceuticals · Updated on 2026-09-28

224

Participants Needed

105

Research Sites

3 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating several investigational compounds for people with moderate to severe atopic dermatitis AD. This multicenter, randomized, double-blind, placebo-controlled Phase II platform study aims to assess the safety and effectiveness of these treatments, with Novartis Pharmaceuticals sponsoring the trial. The study focuses on improving skin symptoms and disease severity in participants diagnosed with AD for at least one year. The first treatment being tested is GHZ339, which will be given in different doses labeled A, B, C, and D. Participants are randomly assigned to study groups where they will receive a specific dose of GHZ339 or a placebo during the first treatment period. In the second treatment period, they continue with the same or adjusted dose, depending on their initial assignment. Placebo recipients in the first period will receive one of the GHZ339 doses during the second period. During the study, participants will have assessments including the Eczema Area and Severity Index EASI to measure disease changes, along with Investigator Global Assessment IGA scores at baseline and at 16 weeks. Researchers will monitor safety through laboratory tests and clinical evaluations. The total duration participants are followed corresponds to the treatment and assessment periods, and the main focus is tracking improvements in skin condition and overall disease status.

CONDITIONS

Brief Title

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here